Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase

Summary

Nitric oxide (NO) regulates both vascular tone and platelet function. Since thrombotic diseases and their animal models consist of both vascular and platelet components, the functional mechanisms by which NO and endothelial nitric oxide synthase (eNOS) regulate thrombotic events are unclear. Experiments were conducted by measuring collagen-induced aggregation of freely circulating radio-labelled platelets in the pulmonary vasculature of anaesthetised mice via external detection probes. In addition, cardiac haemodynamic function was assessed by invasive catheterisation during thrombotic stimulation. Platelet aggregation responses were shown to occur independently of changes in vessel tone induced by pharmacological vasoconstriction or vasodilatation. Acute NOS inhibition significantly potentiated the amplitude and duration of platelet aggregation and an NO donor had an inhibitory effect. In contrast, in eNOS^−/− mice, the amplitude of platelet aggregation was not affected although the response was protracted following moderate thrombotic stimulation. Thrombosis induced changes in haemodynamic performance were sensitive to vasomodulation and were potentiated by both NOS inhibition and in eNOS^−/− mice. In conclusion, endogenous NO and exogenously applied NO donors exert an antithrombotic effect in vivo through a direct suppression of platelet aggregation. In contrast, eNOS exerts a powerful antithrombotic effect upon the vascular components of thrombosis but has a more subtle effect on the duration of thrombotic responses that are platelet-mediated. Our data demonstrate the differential roles of eNOS and general NO bioavailability in regulating vascular and platelet activity during thrombosis.

Keywords

Animal models - endothelium - nitric oxide - pharmacology - platelet

• References

• 1 Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190: 244-254.
• 2 Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
• 3 Day SM, Reeve JL, Myers DD. et al. Murine thrombosis models. Thromb Haemost 2004; 92: 486-494.
• 4 Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006; 15: 318-330.
• 5 Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
• 6 Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Ann Rev Pharmacol Toxicol 1990; 30: 535-560.
• 7 de Graaf JC, Banga JD, Moncada S. et al. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-2290.
• 8 Emerson M, Momi S, Paul W. et al. Endogenous nitric oxide acts as a natural anti-thrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost 1999; 81: 961-966.
• 9 Freedman JE, Loscalzo J, Benoit SE. et al. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest 1996; 97: 979-987.
• 10 Tymvios C, Moore C, Jones S. et al. Platelet aggregation responses are critically regulated in vivo by endogenous nitric oxide but not by endothelial nitric oxide synthase. Br J Pharmacol 2009; 158: 1735-1742.
• 11 Ozuyaman B, Godecke A, Kusters S. et al. Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation. Thromb Haemost 2005; 93: 1161-1167.
• 12 Dayal S, Wilson KM, Leo L. et al. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Blood 2006; 108: 2237-2243.
• 13 Freedman JE, Sauter R, Battinelli EM. et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circulation Res 1999; 84: 1416-1421.
• 14 Iafrati MD, Vitseva O, Tanriverdi K. et al. Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am J Physiol 2005; 288: H1627-1632.
• 15 Heeringa P, van Goor H, Itoh-Lindstrom Y. et al. Lack of endothelial nitric oxide synthase aggravates murine accelerated antiglomerular basement membrane glomerulonephritis. The Am J Pathol 2000; 156: 879-888.
• 16 Huang PL. Mouse models of nitric oxide synthase deficiency. J Am Soc Nephrol 2000; 11 (Suppl. 16) S120-123.
• 17 Harrington LS, Carrier MJ, Gallagher N. et al. Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol 2007; 293: H1682-1688.
• 18 Tymvios C, Jones S, Moore C. et al. Real-time measurement of nonlethal platelet thromboembolic responses in the anaesthetized mouse. Thromb Haemost 2008; 99: 435-440.
• 19 Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 2008; 153 (Suppl. 02) S1-209.
• 20 May GR, Herd CM, Butler KD. et al. Radioisotopic model for investigating thromboembolism in the rabbit. J Pharmacol Methods 1990; 24: 19-35.
• 21 Oceandy D, Cartwright EJ, Emerson M. et al. Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation 2007; 115: 483-492.
• 22 Huang PL, Huang Z, Mashimo H. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
• 23 Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005; 20: 496-501.
• 24 Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121: 877-905.
• 25 Dias-Junior CA, Tanus-Santos JE. Hemodynamic effects of sildenafil interaction with a nitric oxide donor compound in a dog model of acute pulmonary embolism. Life Sci 2006; 79: 469-474.